Diagnosis, clinical features and molecular assessment of the dysfibrinogenaemias

Haemophilia

Volumn 14, Issue 5, 2008, Pages 889-897

  Hill, Marian ^a   Dolan, G ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Dysfibrinogenaemia; Dysfibrinogenemia; Fibrin; Fibrinogen

Indexed keywords

ARGININE; CYSTEINE; FIBRIN; FIBRINOGEN; FIBRINOGEN VARIANT; HISTIDINE;

AMINO ACID SUBSTITUTION; BLEEDING; BLOOD CLOTTING TEST; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DYSFIBRINOGENEMIA; FAMILY STUDY; FIBRINOGEN BLOOD LEVEL; GENETIC VARIABILITY; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; NEUROPATHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT; SCREENING TEST; THROMBOSIS;

AFIBRINOGENEMIA; FIBRINOGENS, ABNORMAL; HEMORRHAGE; HUMANS; MUTATION; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOSIS;

EID: 51249099966     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01795.x     Document Type: Review

References (76)

1. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 3: 1894-904.
2. Degen JL, Bugge TH, Goguen JD. Fibrin and fibrinolysis in infection and host defense. J Thromb Haemost 2007; 5(Suppl. 1): 24-31.
3. Laurens N, Koolwijk P, de Maat MPM. Fibrin structure and wound healing. J Thromb Haemost 2006; 4: 932-9.
4. Koenig W. Fibrin(ogen) in cardiovascular disease: An update. Thromb Haemost 2003; 89: 601-9.
5. Bennett JS. Platelet-fibrinogen interactions. Ann NY Acad Sci 2001; 936: 340-54.
6. Standeven KF, Ariens RAS, Grant PJ. The molecular physiology and pathology of fibrin structure/function. Blood Rev 2005; 19: 275-88.
7. Lord ST. Fibrinogen and fibrin: Scaffold proteins in hemostasis. Curr Opin Hematol 2007; 14: 236-41.
8. Tennent GA, Brennan SO, Stangou AJ et al. Human plasma fibrinogen is synthesized in the liver. Blood 2007; 109: 1971-4.
9. Henschen A, Lottspeich F, Kehl M, Southan C. Covalent structure of fibrinogen. Ann NY Acad Sci 1983; 408: 28-43.
10. Weisel JW. Fibrinogen and fibrin. Adv Protein Chem 2005; 70: 247-99.
11. de Maat MPM, Verschuur M. Fibrinogen heterogeneity: Inherited and noninherited. Curr Opin Hematol 2005; 12: 377-83.
12. Kant JA, Fornace AJ Jr, Saxe D, Simon MI, McBride OW, Crabtree GR. Evolution and organization of the fibrinogen locus on chromosome 4: Gene duplication accompanied by transposition and inversion. Proc Natl Acad Sci US A 1985; 82: 2344-8.
13. Roy S, Overton O, Redman C. Overexpression of any fibrinogen chain by Hep G2 cells specifically elevates the expression of the other two chains. J Biol Chem 1994; 269: 691-5.
14. Fu Y, Weissbach L, Plant PW et al. Carboxy-terminal-extended variant of the human fibrinogen alpha subunit: A novel exon conferring marked homology to beta and gamma subunits. Biochemistry 1992; 31: 11968-72.
15. Mosesson MW, Finlayson JS, Umfleet RA. Human fibrinogen heterogeneities. 3. Identification of gamma chain variants. J Biol Chem 1972; 247: 5223-7.
16. Collen D, Tytgat GN, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. Br J Haematol 1972; 22: 681-700.
17. Redman CM, Xia H. Fibrinogen biosynthesis. Assembly, intracellular degradation, and association with lipid synthesis and secretion. Ann N Y Acad Sci 2001; 936: 480-95.
18. Blomback B, Hessel B, Hogg D, Therkildsen L. A two-step fibrinogen-fibrin transition in blood coagulation. Nature 1978; 275: 501-5.
19. Weisel JW. structure of fibrin: Impact on clot stability. J Thromb Haemost 2007; 5: 116-24.
20. Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982; 35: 667-72.
21. Asselta R, Duga S, Tenchini ML. The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 2006; 4: 2115-29.
22. Neerman-Arbez M. Molecular basis of fibrinogen deficiency. Pathophysiol Haemost Thromb 2006; 35: 187-98.
23. Asselta R, Spena S, Duga S, Tenchini ML. Molecular genetics of quantitative fibrinogen disorders. Cardiovas Hematol Agents Med Chem 2007; 5: 163-73.
24. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4: 1634-7.
25. Girolami A, Ruzzon E, Tezza F, Scandellari R, Vettore S, Girolami B. Arterial and venous thrombosis in rare congenital bleeding disorders: A critical review. Haemophilia 2006; 12: 345-51.
26. Neerman-Arbez M, de Moerloose P. Mutations in the fibrinogen gene cluster accounting for congenital afibrinogenemia: An update and report of 10 novel mutations. Human Mutat 2007; 28: 540-53.
27. Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: From large deletions to intracellular retention of misfolded proteins. J Thromb Haemost 2007; 5(Suppl. 1): 125-31.
28. Maghzal GJ, Brennan SO, Homer VM, George PM. The molecular mechanisms of congenital hypofibrinogenaemia. Cell Mol Life Sci 2004; 61: 1427-38.
29. Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001; 114: 249-57.
30. McDonagh J. Dysfibrinogenemia and other disorders of fibrinogen structure or function. In: Colman R HJ, Marder V, Clowes A, George J, eds. Hemostasis and Thrombosis, 4th edn. Philadelphia, PA: Lippincott Williams & Wilkins, 2001: 855-92.
31. Hanss M BF. A Database for human fibrinogen variants. Ann N Y Acad Sci 2001; 936: 89-90.
32. HGVS. Nomenclature for the description of sequence variations. http://www.hgvs.org/mutnomen/.
33. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73: 151-61.
34. Hayes T. Dysfibrinogenemia and thrombosis. Arch Pathol Lab Med 2002; 126: 1387-90.
35. Mathonnet F, Peltier JY, Roda L et al. Three new cases of dysfibrinogenemia: Poissy III, Saint-Germain I and Tahiti. Thromb Res 2001; 103: 201-7.
36. Bolton-Maggs PHB, Perry DJ, Chalmers EA et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors'Organisation. Haemophilia 2004; 10: 593-628.
37. Mackie IJ, Kitchen S, Machin SJ, Lowe GDO. Haemostasis and Thrombosis Task Force of the British Committee for Standards in H. Guidelines on fibrinogen assays. Br J Haematol 2003; 121: 396-404.
38. Cunningham MT, Brandt JT, Laposata M, Olson JD. Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 2002; 126: 499-505.
39. Lefkowitz JB, DeBoom T, Weller A, Clarke S, Lavrinets D. Fibrinogen Longmont: A dysfibrinogenemia that causes prolonged clot-based test results only when using an optical detection method. Am J Hematol 2000; 63: 149-55.
40. Grimley CHM, Westby J, Dolan G. Appearances can be deceptive: A family with dysfibrinogenemia, Fibrinogen Longmont that causes discrepent clotting times depending on the clot detection mechanism used, but appear not to bleed. Haemophilia 2006; 12: 26.
41. Lounes KC, Lefkowitz JB, Coates AI et al. Fibrinogen Longmont. A heterozygous abnormal fibrinogen with B beta Arg-166 to Cys substitution associated with defective fibrin polymerization. Ann N Y Acad Sci 2001; 936: 129-32.
42. Lounes KC, Lefkowitz JB, Henschen-Edman AH, Coates AI, Hantgan RR, Lord ST. The impaired polymerization of fibrinogen Longmont (Bbeta166Arg->Cys) is not improved by removal of disulfide-linked dimers from a mixture of dimers and cysteine-linked monomers. Blood 2001; 98: 661-6.
43. Mosseson M. Hereditary fibrinogen abnormalities. In: MA Lichtman EB, Kaushansky K, Kipps TJ, Seligsohn U, Prchal J eds. Eilliams Hematology, 7th edn. New York: McGraw-Hill, 2005, 1909: 2005.
44. Martinez J. Congenital dysfibrinogenemia. Curr Opin Hematol 1997; 4: 357-65.
45. Lord ST, Gorkun OV. Insight from studies with recombinant fibrinogens. Ann NY Acad Sci 2001; 936: 101-16.
46. Higgins DL, Shafer JA. Fibrinogen Petoskey, a dysfibrinogenemia characterized by replacement of Arg-A alpha 16 by a histidyl residue. Evidence for thrombin-catalyzed hydrolysis at a histidyl residue. J Biol Chem 1981; 256: 12013-7.
47. Henschen AKM, Kehl M, Southan C, Lottspeich F, Georgopolous D. Genetically abnormal fibrinogens - some current charaterisation strategies. In: Haverkate FHA, Nieuwenhuizen W, Straub PW eds. Fibrinogen: Structure, Functional Aspects, Metabolism. Berlin: Walter de Gruyter, 1983: 125.
48. Alving BM, Henschen AH. Fibrinogen giessen I: A congenital homozygously expressed dysfibrinogenemia with A alpha 16 Arg-His substitution. Am J Hematol 1987; 25: 479-82.
49. Stucki B, Zenhausern R, Biedermann B et al. Fibrinogens Bern IV, Bern V and Milano XI: Three dysfunctional variants with amino acid substitutions in the thrombin cleavage site of the Aalpha-chain. [erratum appears in Blood Coagul Fibrinolysis 1999 Jun;10(4):213]. Blood Coagul Fibrinolysis 1999; 10: 93-9.
50. Flood VH, Al-Mondhiry HA, Farrell DH. The fibrinogen alpha R16C mutation results in fibrinolytic resistance. Br J Haematol 2006; 134: 220-6.
51. Soria J, Soria C, Samama M, Poirot E, Kling C. Fibrinogen troyes-fibrinogen Metz. Two new cases of congenital dysfibrinogenemia. Thromb Haemost 1972; 27: 619-33.
52. Spraggon G, Everse SJ, Doolittle RF. Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin [erratum appears in Nature 1997 Nov 20;390(6657):315]. Nature 1997; 389: 455-62.
53. Ishikawa S, Hirota-Kawadobora M, Tozuka M, Ishii K, Terasawa F, Okumura N. Recombinant fibrinogen, gamma275Arg->Cys, exhibits formation of disulfide bond with cysteine and severely impaired D:D interactions. J Thromb Haemost 2004; 2: 468-75.
54. Borrell M, Gari M, Coll I et al. Abnormal polymerization and normal binding of plasminogen and t-PA in three new dysfibrinogenaemias: Barcelona III and IV (gamma Arg 275->His) and Villajoyosa (gamma Arg 275->Cys). Blood Coagul Fibrinolysis 1995; 6: 198-206.
55. Mimuro J, Kawata Y, Niwa K et al. A new type of Ser substitution for gamma Arg-275 in fibrinogen Kamogawa I characterized by impaired fibrin assembly. Thromb Haemost 1999; 81: 940-4.
56. Sugo T, Endo H, Matsuda M et al. A classification of the fibrin network structures formed from the hereditary dysfibrinogens. J Thromb Haemost 2006; 4: 1738-46.
57. Siebenlist KR, Mosesson MW, Meh DA, DiOrio JP, Albrecht RM, Olson JD. Coexisting dysfibrinogenemia (gammaR275C) and factor V Leiden deficiency associated with thromboembolic disease (fibrinogen Cedar Rapids). Blood Coagul Fibrinolysis 2000; 11: 293-304.
58. Linenberger ML, Kindelan J, Bennett RL, Reiner AP, Cote HC. Fibrinogen bellingham: A gamma-chain R275C substitution and a beta-promoter polymorphism in a thrombotic member of an asymptomatic family. Am J Hematol 2000; 64: 242-50.
59. Keller MA, Martinez J, Baradet TC et al. Fibrinogen Philadelphia, a hypodysfibrinogenemia characterized by abnormal polymerization and fibrinogen hypercatabolism due to gamma S378P mutation. Blood 2005; 105: 3162-8.
60. Gralnick HR, Coller BS, Fratantoni JC, Martinez J. Fibrinogen bethesda III: A hypodysfibrinogenemia. Blood 1979; 53: 28-46.
61. Branson HE, Schmer G, Theodor I, Pirkle H. Fibrinogen Seattle releases half the normal amount of fibrinopeptide B. Acta Haematol 1983; 70: 257-63.
62. Brennan SO, Hammonds B, Spearing R et al. Electrospray ionisation mass spectrometry facilitates detection of fibrinogen (Bbeta 14 Arg-> Cys) mutation in a family with thrombosis. Thrombo Haemost 1997; 78: 1484-7.
63. Koopman J, Haverkate F, Grimbergen J et al. Abnormal fibrinogens IJmuiden (B beta Arg14 -Cys) and Nijmegen (B beta Arg44 -Cys) form disulfide-linked fibrinogen-albumin complexes. Proc Natl Acad Sci USA 1992; 89: 3478-82.
64. Vakalopoulou S, Mille-Baker B, Mumford A, Manning R, Laffan M. Fibrinogen Bbeta14 Arg->Cys: Further evidence for a role in thrombosis. Blood Coagul Fibrinolysis 1999; 10: 403-8.
65. Castaman G, Ghiotto R, Tosetto A, Rodeghiero F. Bbeta 14 Arg > Cys variant dysfibrinogen and its association with thrombosis. J Thromb Haemost 2005; 3: 409-10.
66. de Raucourt E, Fischer AM, Meyer G, de Mazancourt P. A Bbeta 14 Arg -> Cys fibrinogen variant in a patient with thrombotic complications (fibrinogen St-Germain III). J Thromb Haemost 2006; 4: 2722-3.
67. Koopman J, Haverkate F, Grimbergen J et al. Molecular basis for fibrinogen Dusart (A alpha 554 Arg ->Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 1993; 91: 1637-43.
68. Wada Y, Lord ST. A correlation between thrombotic disease and a specific fibrinogen abnormality (A alpha 554 Arg->Cys) in two unrelated kindred, Dusart and Chapel Hill III. Blood 1994; 84: 3709-14.
69. Tarumi T, Martincic D, Thomas A et al. Familial thrombophilia associated with fibrinogen paris V: Dusart syndrome. Blood 2000; 96: 1191-3.
70. Benson MD, Liepnieks J, Uemichi T, Wheeler G, Correa R. Hereditary renal amyloidosis associated with a mutant fibrinogen alpha-chain. [see comment]. Nature Genet 1993; 3: 252-5.
71. Uemichi T, Liepnieks JJ, Benson MD. Hereditary renal amyloidosis with a novel variant fibrinogen. J Clin Invest 1994; 93: 731-6.
72. Brennan SO, Wyatt J, Medicina D et al. Fibrinogen brescia: Hepatic endoplasmic reticulum storage and hypofibrinogenemia because of a gamma284 Gly->Arg mutation. Am J Pathol 2000; 157: 189-96.
73. Brennan SO, Maghzal G, Shneider BL, Gordon R, Magid MS, George PM. Novel fibrinogen gamma375 Arg ->Trp mutation (fibrinogen aguadilla) causes hepatic endoplasmic reticulum storage and hypofibrinogenemia. Hepatology 2002; 36: 652-8.
74. Rubbia-Brandt L, Neerman-Arbez M, Rougemont AL, Male PJ, Spahr L. Fibrinogen gamma375 arg->trp mutation (fibrinogen aguadilla) causes hereditary hypofibrinogenemia, hepatic endoplasmic reticulum storage disease and cirrhosis. Am J Surg Pathol 2006; 30: 906-11.
75. Francalanci P, Santorelli FM, Talini I et al. Severe liver disease in early childhood due to fibrinogen storage and de novo gamma375Arg->Trp gene mutation. J Pediatr 2006; 148: 396-8.
76. Medicina D, Fabbretti G, Brennan SO et al. Genetic and immunological characterization of fibrinogen inclusion bodies in patients with hepatic fibrinogen storage and liver disease. Ann N Y Acad Sci 2001; 936: 522-5.